AC 625

Drug Profile

AC 625

Latest Information Update: 12 May 1997

Price : $50

At a glance

  • Originator Amylin Pharmaceuticals
  • Class Antihypertensives
  • Mechanism of Action Islet amyloid polypeptide inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Hypertension

Most Recent Events

  • 12 May 1997 Discontinued-I for Hypertension in USA (SC)
  • 21 Feb 1996 A study in volunteers has been added to the pharmacokinetics section
  • 29 Jun 1995 This profile has been updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top